Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
HAMPTON, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that the Company and its collaborating investigators will present seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.
Highlights include immune response data from the ongoing Phase 1/2 study of varlilumab and nivolumab in multiple solid tumors, the role of gpNMB as a relevant therapeutic target across multiple cancers and a late-breaking poster from the Phase 1 investigator-sponsored study of CDX-301 (Flt3L) in B-cell lymphomas.
The following Celldex-sponsored abstracts have been selected for poster presentations at AACR:
- Title: Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
Date/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 13
Abstract: CT023
- Title: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma
Date/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 27
Abstract: 5032
- Title: IHC and RT-PCR assays for detection of cancer antigen NY-ESO-1 in human tissues
Date/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 21
Abstract: 1373
- Title: Development and characterization of novel CD40 antibody agonists for cancer immunotherapy
Date/Time: Wednesday, April 20, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 22
Abstract: 4866
The following investigator-sponsored abstracts have been selected for poster presentations at AACR:
- Title: In situ vaccination of low-grade lymphoma with intratumoral Flt3L and poly-ICLC with low-dose radiotherapy
Date/Time: Monday, April 18, 8:00 a.m. – 12:00 p.m. CDT
Location: Section 10
Abstract: LB-081
- Title: Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer
Date/Time: Tuesday, April 19, 1:00 p.m. – 5:00 p.m. CDT
Location: Section 33
Abstract: 4209
- Title: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma
Date/Time: Sunday, April 17, 1:00 p.m. – 5:00 p.m. CDT
Location: Section 16
Abstract: 296
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!